Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer

Early Phase 1

Recruiting

• Conditions: Healthy Human; Lung Cancer
• Interventions: Drug: 68Ga-A3

• Registration Number: NCT06194630
• Lead Sponsor: Peking Union Medical College Hospital

Brief Summary

In the past three years, as the key protein suggested to be involved in host cell entry of SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2 in vivo is crucial to further understanding of COVID-19, dynamically monitoring the effect of antiviral therapy and the development of related vaccines. It is also expected to further conduct in-depth research on the physiological effects of ACE2 and RAAS, and the mechanism of ACEI/ARB (32). With the development of both molecular imaging agents and related equipment, several ACE2-targeting PET imaging agents have been investigated based on different strategies while some of them were tested in clinical trials. The aim of this study was to intercept key ACE2-binding sites from coronavirus RBD and test their potential as ACE2-targeting PET agents.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-11
• Study Start: 2023-11-30
• Primary Completion: 2023-12-12
• Study First Submitted: 2023-12-22
• Study First Submitted QC: 2023-12-22
• Last Update Submitted: 2023-12-22
• Study First Posted: 2024-01-08
• Last Update Posted: 2024-01-08
• Study Completion: 2025-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• the ability to provide informed written consent
• a medical history without any ACE2-related comorbidities

Exclusion Criteria

• liver and renal function dysfunction,
• pregnancy or current lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
68Ga-A3	68Ga-A3	Within 1 week, each participant underwent PET/CT scan after intravenous administration of 68Ga-A3

Primary Outcome Measures

Name	Time	Method
standardized uptake value (SUV)	through study completion, an average of 1 year	comparing the SUVmean of different organs or lesions

Secondary Outcome Measures

Name	Time	Method
Diagnostic performance	through study completion, an average of 1 year	evaluating the number of lung cancer lesions detected by 68Ga-A3

Trial Locations

Locations (2)

Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science; 🇨🇳 Beijing, China

Peking Union Medical College Hospital; 🇨🇳 Beijing, China